Abstract
The effectiveness of transdermally administered clonidine hydrochloride was evaluated in a multicenter study in 85 patients with mild essential hypertension. The drug was incorporated into small self-adhesive delivery systems (pliable skin patches, 3.5-sq-cm area) designed to continuously deliver 0.1 mg of clonidine hydrochloride per day. These devices were changed by the patients themselves at weekly intervals. Diastolic BP fell by at least 10% in 37 patients and was normalized (less than 90 mm Hg) in 54 patients (64%); 17 of these responding patients required only one skin patch, 27 required two, and the other ten responders required three. The antihypertensive action of the transdermal clonidine was sustained for the full three months of study. Side effects were similar to those during conventional oral treatment, but appeared to be milder.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
